Lemaitre Vascular (LMAT) Tops Q2 EPS by 5c, Beats on Revenue; Offers FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
LeMaitre Q2 2024 Financial Results
August 1, 2024 4:06 PM EDTBURLINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq: LMAT), a provider of vascular devices, implants and services, today reported Q2 2024 results, announced a $0.16/share quarterly dividend and provided guidance.
Q2 2024 Financial Results
Sales $55.8mm, +11% (+12% organic) vs. Q2 2023Â Â Gross margin 68.9%, +490 bpsOp. income $14.4mm, +52%Op. margin 26%Net income $11.8mm, +46%Earnings per diluted share $0.52, +44%Cash up $4.8mm sequentially to $113.1mmAllografts (+30%), bovine patches (+12%) and carotid shunts (+22%) led Q2 sales growth. APAC sales increased 20%, EMEA 13% and the Americas 10%.
The gross margin increased... More
